In 2019, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) findings showed that anti-cytokine therapy with a monoclonal antibody against IL-1β improved heart failure outcomes in patients with myocardial infarction with or without established heart failure [8]. The gene discussed is IL1B; the disease is heart failure.